Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
05/12/21 7:03 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- May 12 2021
Summary ToggleAdverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
- May 10 2021
Summary ToggleAdverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
- May 6 2021
Summary ToggleAdverum Reports First Quarter 2021 Results
- May 1 2021
Summary ToggleAdverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
There are currently no events to display.